Preventive Healthcare and Gender Equity: The Case for HPV Immunisation

How India’s nationwide single-dose HPV vaccination programme can transform women’s health outcomes amid global vaccine hesitancy.

Gopi

•February 26, 2026•5 mins read

HPV vaccination: A decisive step toward eliminating cervical cancer in India

Not Started

1. Context: Nationwide Introduction of HPV Vaccination

India’s decision to introduce a nationwide Human Papillomavirus (HPV) vaccination programme for girls aged 14 marks a significant public health intervention. At a time when anti-vaccination sentiments are rising globally, this move reaffirms India’s reliance on scientific evidence and preventive healthcare.

The programme will administer a single-dose vaccine, as recommended by the World Health Organization (WHO), exclusively at designated government health facilities. Vaccination will be conducted under trained medical supervision, with systems in place for post-vaccination observation and management of Adverse Events Following Immunisation (AEFI).

The initiative assumes greater relevance in the global context, where vaccine hesitancy has led to the resurgence of preventable diseases. For example, the United States is currently witnessing a measles epidemic across 26 States, highlighting the consequences of weakening immunisation coverage.

Public health systems depend on sustained trust and scientific credibility. If vaccine hesitancy spreads unchecked, preventable diseases can re-emerge, reversing decades of progress in mortality reduction.

2. Scientific Basis: HPV and Cervical Cancer

Cervical cancer is one of the few cancers with a well-established infectious cause. Persistent infection with high-risk types of HPV—particularly types 16 and 18—is responsible for almost all cervical cancer cases.

In India, HPV types 16 and 18 account for over 80% of cervical cancer cases. The availability of a preventive vaccine makes cervical cancer a rare example where immunisation can directly reduce cancer incidence.

Global experience supports this approach. Over 90 countries have adopted single-dose HPV vaccination schedules. Many of them have demonstrated significant reductions in HPV infections, pre-cancerous lesions, and cervical cancer incidence following widespread vaccination.

"Cervical cancer is largely preventable through HPV vaccination and regular screening." — WHO position reflected in global vaccination policy

The governance logic is clear: when a disease has a known cause and a proven vaccine, prevention becomes more cost-effective than treatment. Failure to act would perpetuate avoidable mortality and health expenditure burdens.

3. Burden of Cervical Cancer in India

India bears a disproportionately high burden of cervical cancer, making vaccination a critical life-saving intervention.

South-East Asia Region (SEARO) has the second-highest cervical cancer incidence and mortality among WHO regions.
India contributes over 65% of the regional burden.

In 2022:

127,526 new cases were reported.
79,906 deaths occurred.
Cervical cancer is the second most common cancer among women in India.

Screening coverage remains extremely low:

Only 1.9% of women aged 30–49 have been tested.

Low screening rates and late detection significantly worsen outcomes, despite cervical cancer being curable if identified early.

High disease burden combined with poor screening coverage makes primary prevention through vaccination indispensable. Ignoring this would sustain high mortality among women, affecting workforce participation, family welfare, and broader human development indicators.

4. Vaccine Hesitancy and India’s Past Controversy

India’s earlier experience with HPV vaccine trials in 2009–10 in Andhra Pradesh and Gujarat continues to influence public perception. Seven girls participating in the trial died during the study period.

An ICMR investigation concluded that the deaths were “most probably unrelated to the vaccine,” though it noted that causation could not be established with complete certainty. Importantly, it highlighted the need for rigorous identification and investigation of AEFI.

Such episodes underscore the fragility of public trust in vaccination programmes. In the current global climate of rising anti-vaccine sentiment, transparent communication and robust monitoring systems are essential.

Public health interventions rely not only on scientific validity but also on social legitimacy. If transparency and accountability are weak, even scientifically sound programmes may face resistance, undermining health outcomes.

5. Implementation Imperatives

For successful nationwide rollout, institutional capacity and operational integrity are critical.

Cold Chain Management:

Continuous temperature-controlled storage and transport must be ensured to maintain vaccine efficacy.

AEFI Monitoring:

Meticulous reporting and investigation mechanisms must function uniformly across States.
Trained medical personnel should manage post-vaccination observation.

Institutional Safeguards:

Vaccination limited to designated government facilities.
Administration under trained medical supervision.
Structured post-vaccination observation protocols.

Transparency & Communication:

Clear dissemination of scientific evidence.
Timely public disclosure of safety monitoring outcomes.

Effective implementation determines whether policy intent translates into measurable health gains. Weak logistics or poor reporting could erode credibility and compromise long-term immunisation goals.

6. Cross-Dimensional Relevance for UPSC

GS Paper II (Governance & Health)

Public health policy
Immunisation programmes
Institutional capacity and accountability
Centre–State coordination in health delivery

GS Paper III (Science & Technology / Social Sector)

Vaccine technology and preventive healthcare
Disease burden reduction
Health infrastructure strengthening

GS Paper I (Society)

Women’s health and gender equity
Impact of preventable diseases on social development

Essay Themes

Preventive healthcare vs curative healthcare
Science, trust and public policy
Women’s health as a development multiplier

Conclusion

India’s nationwide HPV vaccination programme represents a strategic shift toward preventive oncology and evidence-based public health. Given the country’s high cervical cancer burden and low screening coverage, vaccination can significantly reduce preventable deaths among women.

Sustained political commitment, transparent implementation, and robust safety monitoring will determine whether this initiative evolves into a landmark success in India’s public health trajectory.

Quick Q&A

Everything you need to know

The nationwide HPV vaccination programme is rooted in strong epidemiological and scientific evidence linking persistent infection with high-risk Human Papillomavirus (HPV) types—particularly types 16 and 18—to cervical cancer. These two strains account for more than 80% of cervical cancer cases in India. Given that cervical cancer is largely preventable through vaccination and early screening, the introduction of a WHO-recommended single-dose regimen represents a major preventive public health intervention.

India bears a disproportionately high burden of cervical cancer, contributing over 65% of cases in the WHO South-East Asia Region. With over 1.27 lakh new cases and nearly 80,000 deaths reported in 2022, the disease represents not just a medical issue but a socio-economic challenge affecting women in their productive years. Vaccinating girls at age 14—prior to likely exposure to HPV—ensures optimal immune response and long-term protection.

Further, the decision to administer vaccines exclusively in designated government health facilities under trained medical supervision demonstrates a commitment to safety and credibility. Globally, over 90 countries have adopted similar schedules, showing marked reductions in HPV infection and pre-cancerous lesions. Thus, the programme is both evidence-based and aligned with global best practices.

The launch of the HPV vaccination programme comes at a time when vaccine hesitancy has gained traction globally. The resurgence of measles in the United States across multiple States illustrates the consequences of declining immunisation coverage. In such a climate, India’s decision sends a strong message affirming trust in science and evidence-based policymaking.

HPV vaccination is unique because it prevents a form of cancer, making it one of the rare examples where a vaccine has direct oncological benefits. Failure to implement it due to misinformation or distrust could perpetuate avoidable mortality among women. In India, where screening coverage among women aged 30–49 is only 1.9%, vaccination becomes even more critical as a primary preventive tool.

Therefore, beyond health outcomes, the programme symbolises the State’s role in combating misinformation through transparent communication, medical supervision, and robust AEFI monitoring. It reinforces that public health decisions must rest on scientific consensus rather than populist fears.

Effective implementation of the HPV vaccination programme requires a multi-pronged strategy focusing on logistics, transparency, and community engagement. First, maintaining an uninterrupted cold chain system is essential to preserve vaccine efficacy. India’s experience with large-scale immunisation drives such as Mission Indradhanush can be leveraged for infrastructure and last-mile delivery.

Second, meticulous reporting and investigation of Adverse Events Following Immunisation (AEFI) is crucial. India’s past experience with the 2009–10 HPV vaccine trial, where seven deaths were reported though not conclusively linked to the vaccine, underscores the need for transparency. Establishing rapid response medical teams and independent review committees can enhance credibility.

Third, awareness campaigns involving ASHA workers, school authorities, and local leaders can counter misinformation. Lessons from polio eradication efforts show that sustained community engagement builds trust. Combining logistical efficiency with ethical accountability will determine the programme’s long-term success.

While the HPV vaccination programme is scientifically sound, it faces several practical and ethical challenges. One major concern stems from the 2009–10 vaccine trial controversy, where deaths of participants raised questions about informed consent and post-vaccination monitoring. Even though investigations found no direct causal link, public memory of such events can fuel mistrust.

Ethically, ensuring informed consent—especially among minors—requires clear communication with parents and guardians. The government must avoid coercive practices and instead prioritise awareness. Additionally, equitable access across rural and urban regions is critical to prevent widening health disparities.

On the positive side, the benefits are substantial: preventing a largely avoidable cancer, reducing long-term treatment costs, and empowering women’s health. The key lies in balancing urgency with transparency. A robust grievance redressal mechanism, independent oversight, and public disclosure of AEFI data can address ethical concerns while sustaining public confidence.

As a district health officer, my strategy would focus on three pillars: awareness, access, and accountability. First, I would organise community sensitisation drives in collaboration with school authorities, women’s self-help groups, and frontline health workers to explain the link between HPV and cervical cancer, emphasising that the vaccine prevents cancer rather than promoting behavioural change.

Second, I would ensure logistical preparedness by auditing cold chain facilities and training medical staff for AEFI management. Vaccination camps would be conducted in designated government facilities with post-vaccination observation protocols in place.

Third, transparency would be central. Any reported adverse event would be promptly investigated and findings communicated publicly. Drawing lessons from India’s polio eradication campaign, building trust through dialogue and responsiveness can significantly enhance uptake. Such a strategy would not only improve coverage but also strengthen faith in the public health system.